

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB 6/16/1966

Gender: Male

Patient Identifiers: 01234567890ABCD, 012345

Visit Number (FIN): 01234567890ABCD **Collection Date:** 00/00/0000 00:00

Prostate Specific Antigen, Total - Medicare Screening

ARUP test code 0070234

Prostate Spec Ag Total Screen

5.1 ng/mL H (Ref Interval: 0.0-4.0)

INTERPRETIVE INFORMATION: Prostate Spec Ag, Total Screen

The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in individuals with a prostate age 50 years and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or individuals with nonprostatic carcinoma.

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Prostate Spec Ag Total Screen	22-325-105851	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

4848